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1. ABSTRACT 
 
Endoscopic retrograde cholangiopancreatography (ERCP) is a relatively common 
procedure utilizing fluoroscopy in the imaging of bile and pancreatic ducts and is 
used for diagnostic and therapeutic purposes. ERCP usually requires moderate to 
deep sedation to be successful due to considerable discomfort and pain for the 
patient. During the last two decades propofol, has become the sedative drug of choice 
for ERCP. There are several ways to administer propofol sedation.  Traditionally, the 
anesthesiologist administers propofol, but today there are other ways to organize the 
procedural sedation, such as patient controlled sedation (PCS) and patient-
maintained sedation (PMS). All these techniques have their advantages and 
disadvantages and no method has been found to be superior to others. 
Assessment and recording the level of sedation during endoscopic procedures is 
advocated for in guidelines for sedation. There is currently no consensus on which 
method of assessment should be used.  
Doxapram is a respiratory stimulant with both peripheral and central effects. Since 
respiratory depression is a common adverse effect caused by propofol sedation, the 
role of doxapram in ameliorating this depression is worth exploring. 
Routine preoperative laboratory testing (RPLT) has been increasingly been 
questioned and several guidelines are advising against RPLT for surgery and 
endoscopy in general, but studies regarding ERCP and RPLT are lacking. 
Four studies were performed in the gastrointestinal endoscopy unit of Helsinki 
University Hospital. First study (Study I) was a prospective study to investigate how 
PCS is adopted in clinical practice for ERCP and differences in outcomes using 
different sedation methods commonly in use. It included all patients with ERCP 
performed during a one-year period. The analysis of 1196 ERCPs on 956 patients 
revealed that patients using PCS consumed less propofol with a similar incidence of 
adverse effects when compared to the other methods. 
Second study (Study II) was performed to evaluate different methods of assessment 
of sedation used in scientific literature for ERCP sedation, Bispectral index (BiS), 
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Richmond Agitation/Sedation Scale (RASS), a modified Ramsay Sedation Scale 
(mRSS) and modified Observer Assessment of Alertness and Sedation (mOAAS) in 
200 patients with all scales simultaneously used. All scales were found to be reliable 
in assessing the level of sedation when compared to each other. However, in the 
clinical setting of ERCP sedation BiS may be preferable to the other methods because 
it does not require communication with the sedated patient. 
The purpose of the third study (Study III) was to find out if RPLT was useful in 
predicting adverse effects caused by ERCP or sedation in the patient cohort of Study 
I. RPLT included basic blood count, creatinine, potassium, sodium, amylase and 
International Normalized Ratio/thromboplastin time. Multivariate analysis showed 
no association with RPLTs and post-ERCP pancreatitis. The rate of other adverse 
effects related to ERCP was too low for statistical analysis. Respiratory depression 
caused by sedation was not associated with abnormal RPLTs. Cardiovascular 
depression caused by sedation was found to be related to thrombocytopenia and in 
male patients, hyponatremia. The clinical significance of the relation to 
cardiovascular depression remains unclear and is probably related to other health 
issues. 
The fourth study (Study IV) investigated the use of doxapram as an adjunct to BiS-
guided deep propofol sedation in order to reduce respiratory apneic episodes and 
hypoxemia. Fifty-six patients were randomized to receive either doxapram or placebo 
in 1:1 ratio in a prospective double-blinded protocol and resulted with no statistically 
significant differences between the groups.  
In conclusion, no superior method for sedation or for the assessment of sedation for 
ERCP could be identified, but PCS and BiS remain the most clinically desirable 
protocols. The results suggest that the practice of RPLT should be abandoned and an 
individual preoperative laboratory testing should be adopted. Doxapram seems 
ineffective in preventing respiratory depression caused by propofol sedation. 
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3. ABBREVIATIONS 
 
AAS – Anesthesiologist administered sedation 
ASA – American Society of Anesthesiologists 
BiS - Bispectral index 
EEG – electroencephalography 
ERCP - endoscopic retrograde cholangiopancreatography 
ESA – European Society of Anesthesiology 
ESGE - European Society of Gastrointestinal Endoscopy  
ESGENA - European Society of Gastroenterology and Endoscopy Nurses and 
Associates 
EtCO₂ - end tidal carbon dioxide 
HFNO - High flow nasal oxygenation 
IQR - interquartile range 
mOAAS - modified Observer Assessment of Alertness and Sedation 
mRSS – modified Ramsay scale 
PCS – patient-controlled sedation 
PMS - patient-maintained sedation 
PSA - procedural sedation and analgesia 
PK – Prediction probability 
PSC - primary sclerosing cholangitis  
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RASS - Richmond Agitation/Sedation 
RPLT - routine preoperative laboratory testing 
SE – standard error 
SpO₂ - peripheral oxygen saturation 
TASK - TWIK-related Acid Sensitive K channel 
TCI – target-controlled infusion   
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4. INTRODUCTION 
 
Endoscopic retrograde cholangiopancreatography (ERCP) is a very demanding 
endoscopic procedure that gives valuable information about the structure and 
pathology of the biliary and pancreatic ducts and can be used to take biopsies and 
treat obstructed ducts. ERCP was first described in 1968(1) as a diagnostic tool for 
visualizing the duodenal papilla and the pancreatic duct. Since then it has been 
demonstrated to be effective in diagnosing and treating several disorders, such as 
choledocholithiasis, biliary tract obstruction caused by biliary, pancreatic and other 
malignancies , complications of chronic pancreatitis including pancreatic duct 
stenosis and  pseudocysts, primary sclerosing cholangitis (PSC), and postoperative 
biliary or pancreatic  duct complications. It is estimated, that the need for ERCP is 
about 50-100 per 100 000 persons every year and the need will rise as novel 
techniques are developed(2, 3). 
 
 The procedure begins by inserting a duodenoscope into the duodenum via the 
mouth, esophagus and stomach Air or now more commonly carbon dioxide is 
insufflated into the stomach and duodenum to enable visualization of important 
anatomical structures and enable the cannulation of the common bile duct or the 
pancreatic duct through the duodenal papilla. To aid cannulation glucagon or 
hyoscine butylbromide is often administered to reduce intestinal motility. After the 
cannulation fluoroscopy and contrast media is used to visualize either the biliary tree 
or the pancreatic duct, or both depending on the patient. Sphincterotomy using 
electrocoagulation is often required if the patient requires a stent placement of 
removal of biliary or pancreatic stones. Dilation and stent placement in the biliary or 
pancreatic ducts by hydrostatic wire-guided balloon may be needed if strictures of 
the ducts are encountered. The duration of the procedure varies considerably and is 
usually between 10 to 120 minutes depending on the type of procedure and the skill 
and experience of the endoscopist. Difficulty of ERCP is usually assessed by using the 
Schutz scale (4). However, this scale does have its limitations. For example, a grade I 
procedure may be a lot more challenging than a grade III procedure, but the grading 
is determined by the average difficulty of ERCP. 
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A patient experiences mild discomfort, nausea or even severe pain during ERCP 
especially if the ducts need to be dilated. Sedation is usually required to ease 
patient´s experience and to enable the endoscopist to perform the procedure and 
avoid complications. Monitoring during ERCP is often challenging due to prone 
positioning of the patient and the dim lighting of the endoscopy theater. There is not 
a consensus on the optimal method of sedation for ERCP and the approaches vary 
from minimal sedation by intravenous opioids and midazolam sedation to general 
anesthesia(5-7).  
 
ERCP carries potential risks of complications in addition to its usefulness. The 
reported overall rate of complications for ERCP is around 10% but varies a lot 
depending on the study population and type of procedures (8, 9). Mortality rate 
varies similarly and is between 0.2-0.5%(8). The most common complications of 
ERCP are pancreatitis, bleeding, duodenal perforation, cholangitis and 
cardiopulmonary complications. Other possible complications include portal venous 
air or carbon dioxide embolism caused by gas insufflation during the procedure, 
cholecystitis, stent migration, pneumothorax or pneumomediastinum, liver abscess 
and ileus. In order to avoid complications standard preoperative testing and 
pharmacological interventions have been used(10). The value of routine testing has 
been questioned over the past years (11, 12). 
In order to make ERCP bearable and safe for the patient, the present study evaluates 
the sedation protocol (I-II), pharmacological intervention of respiratory depression 
caused by sedation (IV) and the value of routine testing before ERCP (III).  
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5. REVIEW OF LITERATURE 
 
5.1. Procedural sedation 
 
5.1.1. Monitored anesthesia care and procedural sedation and analgesia 
 
American Society of Anesthesiologists (ASA)(13) and European Society of 
Anesthesiology (ESA)(14) have both released guidelines for procedural sedation. 
 The terms monitored anesthesia care or procedural sedation and analgesia are used 
by ASA and ESA respectively. ASA distinguishes monitored anesthesia care from 
moderate sedation in which sedation is administered by the doctor performing the 
procedure. Monitored anesthesia care is defined as a dedicated anesthesia 
professional administering the sedation and analgesia and includes deep sedation 
and even the potential for conversion to general anesthesia when needed. According 
to ESA “Procedural sedation and analgesia involves the use of hypnotic and/or 
analgesic medications to enable effective performance of diagnostic or therapeutic 
procedures effectively, whilst the patient is closely monitored for potential adverse 
effects.”  
There is some controversy whether propofol sedation should be restricted to use by 
anesthesiologists or should non-anesthesiologists be allowed to administer sedation 
by propofol. European Society of Gastrointestinal Endoscopy (ESGE) and the 
European Society of Gastroenterology and Endoscopy Nurses and Associates 
(ESGENA) have published a guideline (15) for non-anesthesiologist administration of 
propofol for gastrointestinal endoscopy, but most national societies of 
anesthesiologists have not endorsed this practice. There is some evidence that this 
practice is safe at least in limited patient groups(16-20). It is also worth noting, that 
the use of propofol is limited to trained anesthesia and intensive care personnel in 
many countries, including Finland. 
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5.1.2. Assessing the level of sedation 
 
There are several different methods for assessing the level of sedation and there is no 
international consensus on which method to use. The guideline by ASA uses a four-
level scale shown in Table 1. 
 
 
Table 1. Continuum of Depth of Sedation, Definition of General Anesthesia, 
and Levels of Sedation/Analgesia 
Functions Minimal 
sedation 
(anxiolysis) 
Moderate 
sedation/analge
sia (conscious 
sedation) 
Deep 
sedation/anal
gesia 
General Anesthesia 
Responsiveness normal 
response to 
verbal 
stimulation 
purposeful 
response to 
verbal or tactile 
stimulation 
purposeful 
response 
after repeated 
or painful 
sedation 
unarousable, even 
with painful 
stimulus 
Airway unaffected no intervention 
required 
intervention 
may be 
required 
intervention often 
required 
Spontaneous 
ventilation 
unaffected adequate may be 
inadequate 
Frequently 
inadequate 
cardiovascular 
function 
unaffected usually 
maintained 
usually 
maintained 
may be impaired 
 
  
13 
 
ESA employs a modified five-level Ramsay sedation scale(14, 21) shown in Table 2 
 
Table 2. Modified Ramsay scale 
 
Level Description 
1 Fully awake 
2 Drowsy 
3 Apparently asleep but rousable by normal sleep 
4 Apparently asleep but responding to standardized physical stimuli (e.g. 
glabellar tap) 
5 asleep but not responding to strong physical stimuli (comatose) 
 
While not identical, there is a considerable overlap between the two scales, and both 
are useful when assessing the level of procedural sedation(22, 23). As indicated by 
the ASA scale, there is a growing need for interventions by the anesthesia provider as 
the level of sedation gets deeper. This puts an additional challenge to sedating 
patients for ERCP as the response of the patients to the drugs given and the 
nociceptive stimuli caused by the procedure are varied both individually and 
according to the stage of the procedure. There are also other means for assessing the 
level of sedation during procedural sedation. Typically, these are adopted from 
intensive care setting, such as Richmond Agitation/Sedation Scale (RASS)(24) 
shown in Table 3 and modified Observer Assessment of Alertness and Sedation 
(mOAAS)(25, 26) shown in Table 4. 
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Table 3. Richmond Agitation/Sedation Scale 
 
Level Description 
-5 Unarousable, no response to voice, physical stimulation or pain 
-4 Deep sedation, responds only to pain (such as bile duct dilatation) 
-3  Moderate sedation, responds to physical stimulation (such as shaking, 
manipulation of the gastroscope) 
-2 Light sedation, responds to repeated loud voice, eyes open <10 seconds  
-1 drowsy, not fully alert, but has sustained awakening  
(eye-opening/eye contact) to voice (>10 seconds)  
0 Alert and calm 
1 Restless, anxious but movements not aggressive, vigorous 
2  Agitated, frequent non-purposeful movement, fights the procedure 
3 very agitated, pulls or removes catheters; aggressive 
4 Combative, violent, immediate danger to staff 
 
Table 4. Modified Observer’s Assessment of Alertness and Sedation 
 
Level Description 
1 No response to painful stimulus 
2 Responds to panful stimulus only 
3  Responds to loud speech 
4 Lethargic response to speech 
5 Awake, responds to speech readily 
 
Other methods for assessing the level of sedation are taken from monitoring of 
general anesthesia using processed electroencephalography (EEG), such as 
Bispectral index (BiS). BiS can be used for assessment of sedation level using all 
hypnotics except Ketamine(27) There have been several studies examining the use of 
BiS in sedation for endoscopy with varying results(28-31) and a recent meta-analysis 
and systematic review by Park et al. (29) found that the use of BiS did reduce the 
total consumption of propofol but did not have an effect on recovery times or adverse 
effects. BiS gives a numerical value of 0-100 based on EEG. There is no definite 
number to aim for when using BiS-guided sedation for ERCP, but BiS level of around 
80 is generally considered sufficient for endoscopy(27) Other methods employing 
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EEG include Spectral entropy and qCON(32), however, these methods have not been 
as extensively studied in sedation of endoscopic procedures as BiS. 
 
5.1.3. Sedative and analgesic medication 
 
Gastrointestinal endoscopies are usually performed with minimal sedation using 
small amounts of benzodiazepines and opioids administered by the endoscopist 
along the lines suggested by the ASA guideline. Typical drugs used are 
benzodiazepines, such as midazolam, diazepam and opioids, like meperidine and 
fentanyl. However, propofol sedation has increased in popularity(33-36) during 
recent years following the EGSE guidelines. Several meta-analyses and review 
articles have been published on sedation for ERCP(5, 37-40), but there is no 
consensus on ideal sedative medication. 
Propofol is a short-acting hypnotic agent that is widely used in anesthesia and 
sedation. It has no analgesic effect, so addition of analgesics is usually indicated in 
procedural sedation. A world-wide survey on endoscopist administered propofol 
sedation showed, that propofol sedation seems to be very safe, with mortality of 1 in 
161515 cases(19, 37) in general endoscopy population and a lot safer than 
administration of benzodiazepines and opioids(37, 41) with mortality rate of 11 in 
100000. A Cochrane review by Garewal et al. found that patients receiving propofol 
sedation had shorter recovery times with no differences in adverse effects when 
compared to patients receiving benzodiazepines and opioids for ERCP(5). Patient 
satisfaction appears to be good and similar to midazolam sedation(42, 43) 
Dexmedetomidine, an α₂-agonist, that is registered for sedation in the intensive care 
setting has recently been given an indication for intravenous procedural sedation by 
European Medicines Agency and it has been studied as a sedative for gastrointestinal 
endoscopy(44-46).  According to studies it would seem to be better than midazolam 
but not superior to propofol in this setting. A study by Mazanikov et al. found that an 
adjuvant dexmedetomidine infusion was detrimental to successful sedation for ERCP 
by propofol-alfentanil PCS at least in alcoholics(47). An interesting off-label use of 
dexmedetomidine is intranasal dosing. Intranasally dexmedetomidine can be 
administered as premedication about 40 minutes prior to the procedure which 
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reduces consumption of other sedatives(48). As dexmedetomidine is a relatively 
recent addition to sedatives, more research on its use in endoscopic sedation is 
warranted. 
Ketamine is an N-Methyl-D-Aspartate receptor antagonist that causes an atypical 
dissociative anesthesia and is used for sedation, anesthesia and analgesia. In 
gastrointestinal endoscopy it is mainly used with pediatric patients(49-52). It can be 
successfully used due to its unique pharmacodynamic profile in patients with 
unstable hemodynamics or whose respiration is easily compromised(53). Ketamine 
reduces consumption of midazolam when sedating high risk patients (54, 55) and gag 
reflex in sub-anesthetic doses(56). 
Etomidate is a GABAA receptor modulator that has been clinically used in Europe 
since 1972. It has a very safe cardiovascular and respiratory risk profile. It also has a 
suppressive effect on the adrenal cortex, which may cause concern in critically ill 
patients. There are two randomized controlled trials investigating sedation with 
etomidate for ERCP(57, 58) and one randomized study for advanced endoscopic 
procedures including ERCP(59). In all these studies etomidate was found to be at 
least as safe as propofol in terms of cardiopulmonary adverse effects. Patient 
satisfaction seems comparable to propofol sedation(57, 59) 
Table 5 presents randomized controlled trials that studied sedation with midazolam, 
propofol and dexmedetomidine for ERCP (43, 60-71).  
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Table 5. Randomized controlled trials studying sedation with midazolam, 
propofol and dexmedetomidine for ERCP 
reference sedative agent results number 
of 
patients 
    
Han, 2017 M vs. Propofol No differences 100 
Kongkam, 2008 Propofol vs. 
M+pethidine 
Better recovery profile 
with Propofol 
134 
Krugliak, 2000  Propofol vs. M Faster recovery and 
lesser hemodynamic 
instability with Propofol 
32 
Jung, 2000 Propofol vs. M Faster recovery with 
Propofol 
80 
Wehrmann, 1999 Propofol vs. 
M+pentazocine 
Propofol more effective, 
faster recovery 
198 
Riphaus, 2005 Propofol vs. 
M+pethidine 
Better co-operation, 
faster recovery, less 
respiratory depression 
during recovery with 
propofol 
150 
Lu, 2018 M+remifentanil vs. 
Dex+remifentanil 
less respiratory 
depression and higher 
patient satisfaction with 
Dex 
198 
Vargo, 2002 Propofol vs. 
M+pethidine 
Faster recovery and 
better patient and 
endoscopist satisfaction 
with Propofol 
75 
Lee, 2011 Propofol+M vs. M better health care 
provider satisfaction 
and patient co-operation 
with Propofol 
222 
Kilic, 2011 M vs. Dex higher endoscopist 
satisfaction with Dex 
50 
Goyal, 2016 Dex+ketamine vs. 
Propofol+fentanyl 
Less hypotension, 
bradycardia and 
hypoxemia but longer 
recovery with Dex 
83 
18 
 
Muller, 2008 Propofol+fentanyl 
vs. Dex 
Shorter recovery and 
less hemodynamic 
instability with Propofol 
26 
Kim, 2014 Propofol+M vs. M Faster sedation and 
recovery and higher 
patient co-operation 
with propofol 
94 
M=Midazolam, Dex=Dexmedetomidine 
 
 
5.1.4. Patient-controlled sedation 
 
Patient-controlled sedation (PCS) was first described in 1991 by Rudkin et al(72). PCS is a 
technique in which patients can self-administer sedative medication according to their 
individual needs during a procedure or for example mechanical ventilation in the intensive 
care unit(73). There are two main methods of PCS. In the first method an infusion pump 
administers preprogrammed boluses of the chosen sedative medication as requested by the 
patient via the use of a hand-held device connected to the infusion pump. It is also possible 
to have a background infusion and a lockout time when using PCS. The second method, 
often called patient-maintained sedation (PMS), employs a target controlled infusion (TCI) 
pump with a timer, which lowers the level of sedation over time unless the patient requests 
a deeper level of sedation by a hand held device attached to the TCI pump, which then 
increases the infusion speed of the sedative. A recent meta-analysis (74) found that PCS 
with propofol had no impact on the risk of oxygen desaturation, but the risk of rescue 
interventions for adverse effects was lower when using PCS when compared to clinician 
administered propofol sedation. However, the authors of the article remarked, that the 
quality of the data was relatively low. Another meta-analysis of PCS for colonoscopy(75) 
found that PCS was as feasible and effective as traditional intravenous sedation for 
colonoscopy and there was a trend towards faster recovery and less oxygen desaturation 
and hypotension. Several studies evaluating PCS for ERCP(76-79) have been performed. PCS 
using propofol with different additives, such as alfentanil and remifentanil, has been found 
to be superior to traditional sedation using midazolam and at least non-inferior to 
anesthesiologist administered propofol for sedation of ERCP patients. 
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5.1.5. General Anesthesia 
 
Data concerning general anesthesia for ERCP is scarce. While conscious sedation of 
varying depth is generally the method of choice for ERCP, general anesthesia is also 
an option that some centers use regularly. Usual indications for general anesthesia 
are related to compliance issues, adverse effects to sedatives, and issues related to 
protecting from  aspiration of gastric contents, airway problems or cardiovascular 
harm(80, 81). There is also some evidence, that general anesthesia may be associated 
with fewer adverse effects than sedation(82). A laryngeal mask airway is also a 
possibility during ERCP(83) and may offer a sort of middle ground between balanced 
general anesthesia and deep sedation, but data is lacking in this regard. A recent 
review article by Goudra et al. concluded, that general anesthesia and endotracheal 
intubation are not required for ERCP, but close monitoring, experienced anesthesia 
staff and the possibility of airway management are paramount(84). 
 
5.1.6. Adverse effects 
 
There are several potential adverse effects related to procedural sedation(14, 85). The 
most important adverse effect is arguably hypoxemia. Hypoxemia can be caused by 
the depression of the respiratory drive caused by sedative medication and opioids as 
the level of sedation deepens. Airway obstruction is also possible, caused by the 
relaxation of the tongue and pharynx due to excessive sedation. These adverse effects 
can be counteracted by naloxone and flumazenil, when caused by opioids and 
benzodiazepines(86). Respiratory support is usually indicated starting from 
supplemental oxygen up to and including endotracheal intubation and mechanical 
ventilation. Aspiration of gastric contents is also a threat, especially when the 
gastrointestinal tract is obstructed, there is gastroparesis or gastric bleeding. 
Administering sedation under such conditions is challenging. 
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Hypotension is about as common adverse effect as hypoxemia in sedation for 
endoscopy in general (87) and ERCP (57, 88). Generally systolic blood pressure of 
90mmHg is considered sufficient for organ perfusion when lying down. Hypotension 
is usually attributed to sedatives or a vasovagal reaction. Both benzodiazepines and 
propofol can cause cardiovascular depression and hypotension, especially in 
conjunction with opioids. Hypotension in procedural sedation is usually corrected 
using standard treatments like correcting hypovolemia and vasoactive medications, 
such as ephedrine or phenylephrine. Myocardial ischemia and infarction are rare 
adverse effects related to sedation during endoscopy, but they may also present 
within a few days following the procedure. Sedation can predispose to myocardial 
ischemia via either hypoxemia or reduced myocardial perfusion, both of which can 
be attributed to sedation. Cardiac arrest can also occur, either due to myocardial 
infarction or other causes, such as air embolism caused by the endoscopy (89, 90). 
 
5.2. Preoperative laboratory tests 
 
Routine preoperative laboratory testing (RPLT) has been usual practice for a long 
time. The goal of RPLT is to detect abnormalities that may cause problems related to 
treatment chosen for a patient. This practice has been increasingly questioned lately 
on virtually all fields of surgery(91-98). The abnormalities found in RPLT seldomly 
affect the procedure(99, 100). There is a dearth of literature regarding the use of 
RPLT for endoscopic procedures, but a position statement by AGSE (101) declares 
that RPLT is not cost effective and may unnecessarily delay endoscopy and subject 
the patient to additional risks. Preoperative laboratory testing should be performed 
based on clinical judgement in an individual case-to case basis. However, RPLT is 
still deeply rooted in clinical practice of high-volume group of ERCP patients. 
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5.3. Doxapram 
 
Doxapram was first synthesized in 1962(102) and is an analeptic drug and a 
respiratory stimulant. Both of these effects were initially thought to occur via 
stimulation of the central nervous system. The respiratory stimulant effect has later 
found to be mediated also by the stimulation of aortic and carotid chemoreceptors, 
specifically TASK-1 and TASK-3 (TWIK-related Acid Sensitive K channel). It is 
currently unclear, whether the central or peripheral effect is more important in 
mediating the respiratory stimulant effect.  
In clinical practice doxapram has been used as a stimulant in respiratory failure 
related to chronic obstructive pulmonary disease(103) and sleep apnea(104). 
However, the effect of doxapram in these indications is not very substantial and 
other newer interventions, such as non-invasive ventilation, are more effective.  In 
the perioperative setting doxapram has been used to facilitate faster recovery from 
general anesthesia because of its analeptic and respiratory stimulant properties. It 
was mostly studied in this setting in the 1960’s and 1970’s (105-108). With the 
advent of newer, faster acting anesthetics the need for analeptic drugs and 
respiratory stimulants has declined. There have been some newer studies done on 
doxapram with general anesthesia(109-111). These studies confirm the older findings 
that doxapram shortens recovery time after general anesthesia, even with modern 
anesthetics. The clinical significance of the shorter recovery time is negligible, on 
average 2-5 minutes faster recovery. The use of doxapram as a method of preventing 
respiratory depression during sedation and anesthesia has not been investigated.  
Like all drugs, doxapram does have some side effects(102), such as cough, dyspnea, 
tachypnea, headache and dizziness. Doxapram has also been associated with 
agitation in the intensive care setting(112). Doxapram is contraindicated in patients 
with obstructed airway and other mechanical restrictions of the chest wall as 
respiratory stimulation may cause increased ventilatory attempts against a closed 
airway which may lead to pulmonary edema.  
22 
 
6.  AIMS OF THE STUDY 
 
The aim of this thesis was to examine different modalities of sedation for improving 
the quality of sedation in ERCP procedures. The specific aims of the four studies 
were: 
I: To examine how PCS was adopted into clinical practice in the endoscopy unit and 
study the differences in the safety profile of different methods of sedation. 
II: To compare different methods for assessing the level of propofol sedation during 
ERCP  
III: To assess the usefulness of routine preoperative laboratory testing for ERCP and 
to find out if some laboratory test results were associated with adverse effects 
IV: To study if the respiratory stimulant doxapram could be used as an additive to 
propofol sedation to decrease the risk respiratory depression during sedation. 
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7.  MATERIALS AND METHODS 
 
7.1. Patients and Study designs 
 
All studies were performed in the endoscopy unit of Helsinki University Central 
Hospital. The population of this thesis consisted of three different groups of patients. 
In two of the studies (I, III) the patient group was all 956 adult patients who had 
ERCP performed on them in the endoscopy unit March 1st, 2012-February 28th, 2013. 
For study II, 200 patients were recruited during December 11th, 2013 to January 
19th,2016. A total of 56 patients were recruited for the last study (IV) during 
November and December of 2016 
Studies I-III were prospective observational studies. Studies I and III consisted of the 
same patient population as mentioned in the previous paragraph. A large prospective 
database was collected and employed in the studies.  All adult patients receiving 
ERCP in the endoscopy unit of HUCH were included in the studies. ERCP and 
sedation details and demographic details were recorded and background information 
on patients´ medication and illnesses were gathered from patient records.  
Study II was a prospective study in which four different methods of assessment 
sedation, mOAAS, modified Ramsay scale (mRSS), RASS and BiS, were 
simultaneously used on each patient recruited to the study. BiS was selected as the 
comparator because it is an objective method as opposed to the other scales which 
rely on the subjective clinical assessment of the other scales.  Exclusion criteria for 
the study were refusal to participate and inability to give an informed consent. All 
other ERCP patients were eligible for the study. 
Study IV was a randomized, double-blinded, placebo-controlled study. A computer-
generated random number list was used with sealed non-opaque envelopes. 
Exclusion criteria for the study were age >75 years, epilepsy, coronary artery disease 
(stable or unstable angina pectoris), chronic obstructive pulmonary disease, acute 
alcohol withdrawal syndrome, allergy to propofol or doxapram, refusal to participate 
in the study, and inability to give an informed consent. 
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7.2. ERCP 
 
ERCP was performed according to standard clinical practice in all the studies by an 
experienced endoscopist. Patients were positioned initially in prone position, but 
adjustments of patient positioning were possible. Carbon dioxide insufflation was 
used to inflate the intestinal lumen and glucagon and buspirone were administered 
to reduce intestinal motility when needed. In studies II and IV endoscopist reported 
satisfaction by a questionnaire examining ease of inserting the duodenoscope, 
patient co-operation, gagging, coughing, belching, distracting movement by the 
patient using a four-step scale from none to plenty. The degree of difficulty of the 
ERCP procedure was assessed by the Schutz scale(4) in all the studies. Antibiotic 
prophylaxis and rectal diclofenac were given according to institutional practice 
guidelines. 
 
7.3. Sedation 
 
Three methods of sedation were used in the studies. Sedation was monitored at all 
times by an anesthesia team consisting of an anesthesiologist and an anesthesia 
nurse, who intervened when needed.   
 
7.3.1. Patient-controlled sedation 
 
PCS was one possible choice for sedation by the anesthesiologist in studies I, II, And 
III. PCS was administered according to standard clinical practice of the endoscopy 
unit. PCS solution contained propofol 8mg/ml and alfentanil 0.06mg/ml. A syringe-
driver with a self-administration unit (Syramed μSP6000; Arcomed AG, Regensdorf, 
Switzerland) was prepared with the PCS solution and the patient could take at will a 
1ml i.v. bolus of PCS solution by pressing the button of the self-administration unit. 
There was no background infusion, lockout time or dose limit. PCS was considered 
successful, if a patient received sedation only through PCS. Thus, any intervention 
(i.e. additional sedation) by anesthesia team deemed PCS episode unsuccessful.  
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7.3.2. Anesthesiologist administered sedation  
 
7.3.2.1. Anesthesiologist administered PCS solution 
 
Anesthesiologist could use the same PCS device and solution as the patient to 
administer sedation for patients in studies I, II and III. The entire sedation could be 
administered by the anesthesiologist using the PCS device or in case PCS was not 
successfully used by the patient the anesthesiologist could take over and stop the 
self-administration by the patient.  
7.3.2.2. Propofol infusion 
 
Propofol infusion was the only option for sedation in study IV and a possible choice 
in other studies. Propofol 10mg/ml solution was used in all studies.  
7.3.3. Doxapram 
 
Use of doxapram to reduce respiratory depression caused by propofol sedation was 
investigated in Study IV. It was administered as an i.v. infusion of 1mg/kg/h and an 
initial bolus of 1mg/kg immediately following the induction of sedation by propofol. 
Additional boluses were given in the event of respiratory depression and hypoxemia. 
Several patients also received doxapram in studies I and III but most, if not all, of 
them were in preparation for study IV and not because of acute respiratory 
depression. 
7.3.4. Additional medication 
 
In addition to PCS solution and propofol infusion there were other drugs used to 
facilitate the procedure. Topical lidocaine spray and intravenous glycopyrronium was 
part of the protocol in study IV and could be used in other studies according to the 
clinical judgement of the anesthesiologist. Lidocaine was also part of the lubricant 
used to ease the swallowing of the duodenoscope. As ERCP can cause significant 
pain, opioids were administered as needed, fentanyl being usually the first choice 
and alfentanil occasionally given according preferences of the treating 
anesthesiologist. Ketamine was also used as needed when deemed necessary by the 
anesthesiologist. Midazolam and diazepam and naloxone in addition to propofol 
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were used sporadically in studies I and III and not at all in studies II and IV, so any 
analysis of their use is unfeasible. 
 
7.4. Routine preoperative laboratory tests 
 
The following laboratory tests were taken from all patients in studies I and III: basic 
blood count (BBC), electrolytes (P-Na and P-K), thromboplastin time (P-TT) and 
international normalized ratio (P-INR), amylase levels before the procedure and 4 
and 24 h after the procedure 
 
7.5. Measurements 
 
7.5.1. Primary outcome measures 
 
In study I the primary outcome measures were choice of sedation and successful use 
of PCS. Correlation of the different sedation scales was the primary outcome measure 
of study II. BiS was divided to three categories in study II: light sedation, when Bis 
was over 85, moderate sedation 65 to 85 and deep sedation below 65. Primary end 
points of study III were adverse effects related to ERCP, sedation or both. In study IV 
the primary outcome measures were apneic episodes (patient does not breathe for 30 
seconds) and hypoxemia (SpO₂ below 90 %). 
7.5.2. Secondary outcome measures 
 
Secondary outcome measures for study I were respiratory and cardiovascular 
depression (systolic blood pressure <90mmHg) and the consumption of sedatives 
and opioids. In study II the secondary outcome measures were method of sedation, 
sedation related adverse effects and consumption of medication. The secondary 
outcome measures for study III were laboratory test results, comorbidities and 
medication of the patients. Anemia, hyponatremia, and thrombocytopenia were 
defined as test results level below reference values. In study IV the secondary 
outcome measures were peripheral oxygen saturation (SpO₂), blood pressure, heart 
rate, respiratory rate, end tidal carbon dioxide (EtCO₂), BiS, mOAAS and drug 
27 
 
consumption during the procedure, blood pressure, heart rate, respiratory rate, 
Gilham score and Aldrete score during recovery and patient and endoscopist 
satisfaction. The need for mask ventilation was recorded in all the studies. 
 
7.6. Statistical analysis 
 
The results are reported as median and interquartile range (Studies I-IV) or mean 
and standard deviation (Study IV) as appropriate. Logistic regression analysis was 
used in study I to assess the risk of failure of PCS and the factors affecting the choice 
of sedation method. It was also used in study III to assess the risk of adverse effects. 
In both studies forward stepping was used with p<0.05 criteria. 
In study II Prediction probability and Spearman correlation coefficient were 
calculated to show the relationships between the studied sedation scales and BiS. 
Cronbach’s alpha was calculated to determine the consistency of the scales with 
respect to one another. Multilevel ROC-curves were used to illustrate specificity and 
sensitivity of the scales in relation to BiS. Spearman correlation coefficient and 
prediction probability PK of the different sedation scales in relation to BiS were 
calculated to see how well the scales predict the order of two observed sedation scales 
and endoscopist satisfaction. 
In study IV the Mann-Whitney U-test and Fisher’s exact test were used to test the 
possible differences between the groups.  Mixed effects modelling was used to 
account for repeated measurements on the same subject and comparing results 
between the groups. For continuous variables a linear model was used and 
multinomial logistic regression model for ordinal variables. A separate mixed effects 
model was also used on each group to analyze the possible time dependency within 
the group. A power analysis was performed before the study. At least 18 patients per 
group were required to detect a 30% difference in respiratory depression between the 
groups (β = 0.1, α < 0.05). 
Statistical calculations were generated using IBM SPSS statistics 19 (International 
Business Machines Corporation, Endicott, NY, USA) for study I, IBM SPSS Statistics 
24 (International Business Machines Corporation, Endicott, NY, USA), Medcalc 
Statistical software v 17.6 (Ostend, Belgium) and R v 3.3.2 (12) with pROC 
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package(13) for study II, IBM SPSS Statistics 21 (International Business Machines 
Corporation, Endicott, NY, USA) for Study III and IBM SPSS Statistics 24 
(International Business Machines Corporation, Endicott, NY, USA) for Study IV. 
 
7.7. Ethical concerns 
 
All studies were conducted according to the WMA declaration of Helsinki and 
approved by the Ethics committee of Helsinki University Central Hospital (Ethics 
Committee, Department of Surgery, Biomedicum Helsinki 2 C, Tukholmankatu 8C, 
PL 705, 00029 HUS, Finland). Studies II and IV were also registered in the 
Clinicaltrials.gov database and Study IV was approved by the Finnish Medicines 
Agency (FIMEA) and registered in the EudraCT-system. Informed consent was 
acquired on the day of the procedure for studies II and IV. The need for informed 
consent was waived by the ethics committee for studies I and III. 
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8. RESULTS 
 
A total of 733 patients had PCS with success rate of 77 % (565 of 733). AAS with PCS 
solution was used in 286 patients and AAS with propofol -infusion was used in 429 
patients. The demographics of the patients are shown in Table 6. The discrepancy 
between the number of patients and procedures is due to some patients having more 
than one ERCP performed on them. 
 
  
Table 6. Demographics of the studies 
 
 Study I, III Study II Study IV 
Patients, n 956 200 56 
Gender (Male/Female) 529/427 122/78 N/A 
Age, years, median (IQR) 59 (25) 56 (25.3) 49 (18) 
Body mass index, kg/m² 
median (IQR) 
25.0 (6.2) 25.0 (4.9) 25.7 (6.9) 
ASA class, I/II/III/IV/V 
 
35/417/582/160/
2 
10/86/69/35
/0 
5/29/21/0/
0 
IQR=interquartile range, ASA class=American Society of Anesthesiologists 
physical status classification 
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8.1. ERCP details 
 
Details of ERCP in each study are shown in Table 7. Patients usually have several 
procedures done on them during ERCP. The difficulty of ERCP according to Schutz 
scale in Study I and III was grade 1: 332 (28%), grade 2: 484 (41%), grade 3: 325 (27%) 
and Grade 4: 52 (4%), in study II: grade 1: 112 (56%), grade 2: 28 (14%) and grade 3: 
60 (30%) and in study IV: grade 1: 35 (62%)., grade 2: 4 (7%) and grade 3: 17 (30%) 
 
Table 7. ERCP details in the studies I-IV 
 
ERCP procedure Study I, 
III 
Number 
(%) 
Study II 
Number 
(%) 
Study IV 
Number 
(%) 
Biliary cytology 416 (35) 79 (40) 26 (46) 
Biliary sphincterotomy 562 (47) 49 (25) 13 (23) 
Common bile duct stone extraction  345 (29) 16 (8) 2 (4) 
Biliary dilatation 164 (14) 29 (15) 9 (16) 
Biliary stent application, exchange or removal 357 (30) 51 (26) 12 (21) 
Pancreatic sphincterotomy 207 (17) 7 (4) 3 (5) 
Pancreatic cytology 35 (3) 5 (3) 4 (7) 
Pancreatic dilatation 101 (8) 16 (8) 8 (14) 
Pancreatic stent application, exchange or removal 216 (8) 33 (17) 11 (20) 
Pseudocystogastrostomy or duodenostomy 24 (2) 1 (1) 1 (2) 
Peroral cholangioscopy 21 (2) 5 (3) 2 (4) 
Double balloon ERCP 8 (1) 6 (3) 0 (0) 
Procedure duration, minutes, median (IQR) 23 (19) 23.5 
(17.3) 
20 (16) 
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8.2. Adverse effects of ERCP 
 
The rate of ERCP related adverse effects in the study population included in studies I 
and III was 8.9% (107 adverse effects in 1196 procedures) when all the procedures 
and generally accepted adverse effects were accounted for. Adverse effects related to 
ERCP are shown in Table 8. Milder forms of adverse effects, such as pain in the 
stomach and nausea are not considered ERCP-related adverse effects in this context.  
 
 
Table 8. Adverse effects related to ERCP in studies I and III 
 
 
Adverse effect number 
(percentage
) 
Pancreatitis 43 (3.6) 
Bleeding 17 (1.4) 
Cholangitis 17 (1.4) 
Periampullary perforation  6 (0.5) 
Miscellaneous (pseudocyst infection, air embolism, stent rupture, 
etc.) 
19 (1.6) 
Cardiopulmonary (myocardial infarction, pulmonary embolism) 5 (0.4) 
Mortality, 1-day 2 (0.1) 
Mortality, 1-week 10 (0.8) 
Mortality, 30-day 44 (3.7) 
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8.3. Adverse effects related to sedation 
 
A total of 247 patients (17 %) presented with adverse effects related to sedation. The 
most common adverse effect was respiratory depression and its frequency was twice 
as high in study IV compared to that in study I (and III). The overall rate of adverse 
effects is shown in Table 9.  
 
 
Table 9. Sedation related adverse effects in studies I-IV 
Adverse effect Study I, III, 
 n 
(percentage) 
Study II, 
n 
(percentage) 
Study IV, 
n (percentage) 
Respiratory depression 128 (11) 5 (3) 13 (23) 
Mask ventilation 15 (1) 0 (0) 2 (4) 
Cardiovascular depression 86 (7) 15 (8) 0 (0) 
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PCS was used to sedate patients in studies I-III. Table 10 illustrates the sedation 
related adverse effects when PCS was the method of sedation. 
 
  
Table 10. Adverse effects for patient-controlled sedation in studies I, II and III 
Studies (number of patients) Respiratory 
depression, 
n (percentage) 
Mask 
ventilation, 
n 
(percentage) 
Cardiovascular 
depression, 
n (percentage) 
    
PCS, overall (733) 71 (9,7) 10 (1,4) 42 (5,7) 
PCS, successful (565) 46 (8,1) 2 (0,4) 22 (3,9) 
PCS, unsuccessful (168) 25 (14,9) 8 (4,8) 20 (11,9) 
PCS=patient-controlled sedation    
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Propofol infusion was used in all the studies. Both PCS solution administered by the 
anesthesiologist using the PCS device and propofol infusion were chosen according 
to the clinical judgement and preferences of the treating anesthesiologist. Sedation 
related adverse effects with anesthesiologist administered sedation are illustrated in 
table 11. Cardiovascular depression and respiratory depression were detected with 
equal frequency in AAS patients. 
 
Table 11. Adverse effects for anesthesiologist administered sedation in studies I-
IV 
Studies (number of 
patients) 
Respiratory 
depression, 
n (percentage) 
Mask 
ventilation, 
n (percentage) 
Cardiovascular 
depression, 
n (percentage) 
All studies:     
PCS by anesthesiologist 
(286) 
30 (10,5) 1 (0,3) 26(9,1) 
Propofol infusion (429) 45 (10,5) 6 (1,4) 33 (7,7) 
PCS = Solution used for patient-controlled sedation 
 
8.4. Patient-controlled sedation  
 
Patients sedated with PCS required less propofol for ERCP than patients treated with 
AAS. Median (IQR) consumption of propofol for PCS was 140 (110) mg and 189 (216) 
mg for other sedation methods in study I and III and 176 (76) mg and 197 (210) mg 
for other methods in study II (p<.001 in both studies).  Patients in Studies I-III also 
received a lighter sedation with PCS than other methods of sedation (p<0.001). 
There were no statistically significant differences in Fentanyl consumption between 
the groups in either study. PCS group received more alfentanil due to PCS solution in 
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both studies (p<.001), but the use of additional boluses was so rare that statistical 
analysis was not feasible. There was no statistically significant difference in the 
duration of the procedure in either study with regard to PCS vs. AAS (p=.1 and p=.18 
in studies I/III and II, respectfully). In study II patient and endoscopist satisfaction 
was high in both groups with no statistical differences. The level of sedation was 
lighter with PCS than AAD in studies I-III (p<.001). 
 
8.5. Sedation scales 
 
All sedation scales used reliably assessed the sedation level. Table 12 shows the 
results of Cronbach’s alpha for the different sedation scales. 
 
Table 12. Cronbach’s alpha, including mOAAS, RASS, mRSS, 
BiS 
 
     
Cronbach’s alpha 0.9428    
95% lower confidence limit 0.9381    
     
Variable dropped: mOAAS RASS mRSS BiS 
Alpha 0.9406 0.9018 0.9114 0.9745 
Change -
0.03645 
-
0.04094 
-0.0314 0.03174 
mOAAS = modified observer’s assessment of agitation and sedation, RASS = 
Richmond Agitation/Sedation scale, mRSS = modified Ramsay sedation scale, BiS 
= Bispectral index 
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Observational scales were all statistically significantly correlated with BiS. Number of 
data points per patient for each variable was 6 (3,25). PK and Spearman correlation 
coefficient of the scales compared to BiS are shown in table 13.  
 
 
Table 13. Prediction probability PK and Spearman correlation 
coefficients 
    
 mOAAS RASS mRSS 
Somer’s D 0.40 0.39 0.39 
SE 0.01 0.01 0.01 
p <.01 <.01 <.01 
PK 0.699 0.697 0.695 
SE 0.01 0.01 0.01 
Spearman correlation coefficient 0.695 0.6783 0.673 
SE 0.016 0.017 0.017 
p <.01 <.01 <.01 
mOAAS = modified observer’s assessment of agitation and sedation, RASS = 
Richmond Agitation/Sedation scale, mRSS = modified Ramsay sedation scale, SE 
= standard error,  
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8.6. Routine preoperative laboratory testing 
 
RPLT was done to all patients but could not predict adverse effects related ERCP in 
study III. The results of the RPLT are shown in table 14. 
   
   
Table 14. Routine Preoperative Laboratory 
Test results 
 
Test Result, median 
(IQR) 
Reference values 
Hemoglobin (B-Hb, g/L):   
-males  135 (29.5) 134-167 
-females 122 (20) 117-155 
Platelet count (10E9/L) 243 (126) 150-360 
Potassium (P-K, mmol/L) 3.9 (0.53) 3.3-4.9 
Sodium (P-Na, mmol/L) 139 (4) 137-145 
 Thromboplastin time (P-TT, 
%) 
95 (41) 70-130 
International Normalized 
Ratio (P-INR) 
1.1 (0.2) 2-3 (patients on 
anticoagulants) 
 
Adverse effects related to sedation were associated with some laboratory test results. 
Anemia was associated with fewer respiratory depression incidents (OR 0.26, p<.001) 
if the patient had no cardiovascular disease. Hyponatremia (OR 2.22, p=.001) and 
thrombocytopenia (OR 1.87, p=.025) were found to be risk factors for cardiovascular 
depression, and men with hyponatremia (OR 3.66, p<.001) presenting greater risk 
compared to women with hyponatremia (OR 1.09, p=.078). 
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8.7. Doxapram 
  
All 56 patients recruited in Study IV completed the study and were included in the 
analysis. Doxapram was not found to be effective in reducing respiratory depression 
in study IV. There were no statistically significant differences between the group 
receiving doxapram (group DOX) and the control group (Group P).  Doxapram did 
not reduce the incidence of either apneic episodes (20 in 17 patients in group P, 15 in 
11 patients in group DOX, p=.18) or hypoxemia (7 in 5 patients in group P, 11 in 8 
patients in group DOX, p=.53). Additional doxapram boluses were given in both 
groups (3 in group P and 1 in Group DOX, p=.61). Doxapram did not have any effect 
on patient recovery or patient and endoscopist satisfaction. No adverse effects 
attributable to doxapram was observed.  
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9. DISCUSSION 
 
The present results show that PCS with propofol / alfentanil -mixture was feasible 
sedation protocol for ERCP. The present study suggests that there may be fewer 
adverse effects with PCS compared to those with AAS. RPLT was not able to detect 
patients prone to adverse effect of ERCP. In addition to observational scales, the level 
of sedation is possible to monitor with EEG -based BiS.  
 
9.1. Patient-controlled sedation 
 
PCS has been shown to be a viable option for sedation during ERCP in previous 
studies(78, 79) and this was further confirmed in the studies I-III. Patient and 
endoscopist satisfaction were recorded in study II and they were comparable to AAS, 
both were very high.  There were not any statistically significant differences in 
sedation related adverse effects between PCS and propofol infusion in studies I and 
III. PCS showed favorable cardiovascular profile in Study II compared to AAS. These 
findings are in accordance with other studies(74). This discrepancy can be explained 
by the amount of propofol the patients received during sedation. Patients using PCS 
successfully administered half the amount of propofol when compared to propofol 
infusion. According to the meta-analysis by Kreienbühl from 2018(74) there was no 
difference in propofol consumption with PCS and AAS. However, that meta-analysis 
was about PCS in general and not exclusive to endoscopy. The clinical practice of 
sedation for ERCP in our clinic tends to be a very deep propofol sedation which 
explains the difference. PCS also led to lower levels of sedation, which while not 
affecting the duration of ERCP significantly may well lead to more rapid recovery 
times and thus lower total health care costs.  
All that being said, there are still problems with PCS. PCS requires the patient to take 
charge of their sedation. While the method is relatively simple, the patient must be 
well informed on the mechanics of PCS and even early phases of dementia may 
impair cognition sufficiently that PCS is not feasible, especially during sedation. 
Some discomfort must also be accepted by the patient since the sedation is delivered 
on demand and the level of discomfort varies quite a bit during ERCP. However, 
patient satisfaction seems to be high and comparable to AAS despite this (78, 79). 
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9.2. Assessment of sedation level 
 
Study II found that all the studied sedation scales had good correlation with each 
other. As such all of them can be used to assess depth of sedation during ERCP. An 
issue with the sedation scales currently used in clinical practice is the lack of 
objectivity. These scales are dependent on the subjective assessment of the clinician 
observing the patient. While the scales are generally found to have good inter-
observer validity and reliability(113, 114), the lack of objectivity may result in poor 
sedation.  
There are EEG-based depth of anesthesia monitors in clinical use, such as BiS, E-
Entropy, Narcotrend and qCON. Of these, BiS has been used most in clinical 
research for endoscopic sedation. These monitors do not require the patient to react 
to specific stimuli and as such facilitate uneventful procedures and sedation. Also, 
the depth of sedation can be titrated more accurately than by clinical observation of 
the anesthesia provider since arousal can be observed before the patient regains 
consciousness. However, the actual clinical impact of EEG-based depth of sedation 
monitoring has not been shown in current research. While studies tend to show more 
stable level of sedation and lower consumption of sedatives, the clinical outcomes, 
i.e. adverse effects such as cardiovascular and respiratory depression tend not to be 
improved with statistical significance(29, 30). The objective nature of these monitors 
is a point in their favor as opposed to the subjective assessment of sedation using 
more traditional sedation scales. 
There are several guidelines regarding sedation for gastrointestinal endoscopy and 
they all instruct clinicians to assess the level of sedation in some manner (13-15, 23, 
115, 116). There is no consensus on the method of assessment though, and there is a 
lot of variation in the practices of assessing sedation level in different clinics and 
countries(117).  
One problem with assessment of sedation is the fact, that most sedation scales are 
developed for use in the intensive care setting and validated for that use and not for 
procedural sedation. The problem arises when the scales used require a response to 
certain stimuli such as response to verbal command. If the patient is adequately 
sedated before determining the level of sedation, the arousal caused by the 
assessment may cause the level of sedation to become inadequate during a 
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procedure. While the arousal is not problematic in the intensive care unit and usually 
is even the desired effect(118), it may be detrimental during a demanding endoscopic 
procedure such as ERCP, which is another point in favor of EEG-based depth of 
anesthesia monitors. 
 
9.3. Preoperative laboratory testing 
 
Study III added confirmation to the current trend of eliminating unnecessary 
laboratory testing preoperatively. Both AGSE(101) and the British NICE 
guidelines(119) advice against routine preoperative laboratory testing. The NICE 
guideline is about elective surgery but can be extrapolated from that setting into 
endoscopy. Even the AGSE guideline is forced to extrapolate the findings from 
surgical series since the scientific literature concerning endoscopy is limited in this 
setting. 
Even before Study III, there were plenty of studies advocating for elimination of 
routine preoperative testing for surgery(91, 120-123). According to these studies the 
use of RPLT is not cost effective and may even be harmful to the patient. An 
innocuous abnormality may lead to unnecessary further testing and may expose the 
patient to risks such as delays to necessary procedures due to controlling harmless 
abnormalities in test results or infection from blood sampling.  
As RPLT has not been found to effectively predict adverse effects, the practice should 
be eliminated, and it would seem prudent to limit laboratory testing before ERCP to 
select groups of patients and to prescribe only the tests that are clinically relevant. 
This change in practice may lead to significant financial savings in the long run.  
 
9.4. Doxapram  
 
Doxapram was not found to be effective in reducing respiratory depression in study 
IV. There were fewer patients with apneic episodes and patients requiring additional 
doxapram boluses in the doxapram group, but more patients with hypoxemia in that 
group. No statistically significant differences were found between the groups in any 
of the primary outcomes. There is a possibility of a type II error, since the number of 
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patients in the study was limited, but these findings do not warrant a larger study 
with the same protocol.  
The dosage of doxapram used in study IV was quite low, while still within the doses 
given in previous studies(102). This was done in order to avoid the possible analeptic 
effect of doxapram. It is possible that using a higher dose could have yielded a more 
favorable outcome.  After all, the amount of doxapram the patients received was well 
below the toxic level of 130mg/kg/day and lower than the dosages used for 
respiratory failure before more modern ventilatory systems.  
It is also worth noting, that the level of sedation used in study IV was very deep, 
practically general anesthesia. A moderate level of sedation for ERCP has been used 
in several studies, corresponding to BiS level of approximately 60-80(28, 124, 125). A 
lower level of sedation would most likely lead to less profound respiratory depression 
and enable doxapram to have the desired stimulatory effect with the chosen dosage. 
 
9.5. Limitations 
 
There are some limitations in these studies. All the studies were single center studies, 
so their applicability may not be universal. In study I the reason for selection of 
sedation method was not recorded and the lack of randomization may have on effect 
on the results. In study II the level of sedation was not determined beforehand but 
decided on a case-by-case basis by the attending anesthesiologist which limits the 
scope of the study to the comparison of the studied sedation scales and cannot be 
used to determine other modalities, such as the optimal level of sedation for ERCP. 
In study III the amount of some adverse effects was so low that the statistical 
analysis of their risk factors and was not feasible. The number of patients in study IV 
was relatively low, which does not enable conclusions about the efficacy of the 
treatment with certainty. Exclusion criteria can also influence the results of study IV. 
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10. CLINICAL IMPLICATIONS AND FUTURE 
CONSIDERATIONS 
 
The most important finding was that it is safe and economical to forgo routine 
preoperative laboratory testing and switch to prescribing laboratory testing only as 
needed based on the needs of the individual patient or some beforehand determined 
patient population (study III). This will reduce the costs of health care and the 
inconvenience caused to the patient by excessive laboratory testing.  
Study I found that PCS was an acceptable method for sedation for ERCP with a safety 
profile comparable to traditional propofol sedation in normal clinical practice. As 
none of the studied methods of sedation was found to be superior when compared to 
others, an optimal choice of sedation for ERCP could not be determined.  
 
Study II provides data to clinicians on how to assess the level of sedation during 
procedural sedation. As guidelines recommend recording the sedation level in 
anesthesia records, it cannot be ignored, and study II provides some tools to do it. 
While there is no consensus on what method should be used to assess the depth of 
sedation during ERCP, study II shows that all the scales used in the study can be 
used. As discussed above, it may be that BiS is the most useful of these scales, but 
further studies are needed, also using other EEG-based depth of anesthesia 
monitoring devices. Also, study II was not set up to find an optimal sedation level to 
aim for during ERCP which is a very important question that remains to be 
answered. 
Doxapram was not found to be effective in reducing respiratory depression during 
deep propofol sedation for ERCP (study IV). Further studies with different dosing 
regimens and sedation depths could give the answer whether doxapram has a place 
in modern sedation practice for endoscopies. In recent years a new exciting 
possibility has emerged(126, 127). High flow nasal oxygenation (HFNO) can be used 
to oxygenate patients in apnea for up to 45 minutes. Naturally this needs to be 
studied further, but if such apnea times can be safely reached during ERCP with 
HFNO, the need for respiratory stimulants will be non-existent.  
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11. CONCLUSIONS 
 
There are several conclusions that can be derived from the data of this thesis. 
1. Patient-controlled sedation and anesthesiologist administered sedation are 
both acceptable methods of sedation for ERCP. The method of choice is 
determined by the preferences of the anesthesia provider and the individual 
characteristics of the patient. 
2. BiSpectral index, modified observer’s assessment of agitation/sedation, 
Richmond agitation sedation scale and the Ramsay sedation scale are all valid 
methods of assessing the level of sedation during ERCP. However, BiSpectral 
index being objective and requiring no interaction with the patient is 
preferable in clinical practice. 
3. Routine preoperative laboratory testing should be abandoned, and tests 
should be prescribed individually based on the individual characteristics of 
the patient. 
4. Doxapram infusion (1mg/kg/h) does not reduce respiratory depression caused 
by deep propofol sedation during ERCP 
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